stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) EBITDA
ACADIA Pharmaceuticals Inc.'s EBITDA for fiscal 2025 was $111.1M, down 53.2% from $237.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $96.1M. Over the past ten years it has ranged from −$290.0M (fiscal 2017) to $237.4M (fiscal 2024); the current reading is higher than 91% of that period. ACADIA Pharmaceuticals Inc. ranks 26th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $111.1M | (53.18%) |
| FY2024 | $237.4M | — |
| FY2023 | −$75.4M | — |
| FY2022 | −$224.3M | — |
| FY2021 | −$164.7M | — |
| FY2020 | −$282.2M | — |
| FY2019 | −$247.4M | — |
| FY2018 | −$245.0M | — |
| FY2017 | −$290.0M | — |
| FY2016 | −$270.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $40.9M | — |
| Mar 2026 | −$2.1M | — |
| Dec 2025 | $19.6M | (47.76%) |
| Sep 2025 | $37.6M | 11.34% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. | $96.1M |
| TNGX Tango Therapeutics, Inc. compare | −$137.8M |
| PBLS Parabilis Medicines, Inc. compare | −$172.4M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$261.9M |
| IRON Disc Medicine, Inc. compare | −$273.8M |
| RLAY Relay Therapeutics, Inc. compare | −$311.6M |
| XENE Xenon Pharmaceuticals Inc. compare | −$439.2M |
| DYN Dyne Therapeutics, Inc. compare | −$536.1M |
| VKTX Viking Therapeutics, Inc. compare | −$652.8M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement